CA2509421C - Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside - Google Patents
Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside Download PDFInfo
- Publication number
- CA2509421C CA2509421C CA2509421A CA2509421A CA2509421C CA 2509421 C CA2509421 C CA 2509421C CA 2509421 A CA2509421 A CA 2509421A CA 2509421 A CA2509421 A CA 2509421A CA 2509421 C CA2509421 C CA 2509421C
- Authority
- CA
- Canada
- Prior art keywords
- madecassoside
- mixture
- terminoloside
- extract
- centella asiatica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NNWMHSNRRWMMBI-PJISEHJASA-N Asiaticoside B Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)C[C@@H](O)[C@H]6[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O NNWMHSNRRWMMBI-PJISEHJASA-N 0.000 title claims abstract description 300
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 title claims abstract description 220
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 title claims abstract description 155
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 title claims abstract description 155
- 229940090813 madecassoside Drugs 0.000 title claims abstract description 154
- 238000000034 method Methods 0.000 title claims abstract description 42
- 229940059958 centella asiatica extract Drugs 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 claims abstract description 212
- 239000000284 extract Substances 0.000 claims abstract description 68
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 65
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 65
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 65
- 244000146462 Centella asiatica Species 0.000 claims abstract description 49
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 48
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 40
- 229920005989 resin Polymers 0.000 claims description 40
- 238000000605 extraction Methods 0.000 claims description 33
- 239000012071 phase Substances 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 125000000129 anionic group Chemical group 0.000 claims description 27
- 230000002757 inflammatory effect Effects 0.000 claims description 26
- 239000008346 aqueous phase Substances 0.000 claims description 18
- 201000004681 Psoriasis Diseases 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 17
- 230000001476 alcoholic effect Effects 0.000 claims description 16
- 125000002091 cationic group Chemical group 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 11
- 230000002500 effect on skin Effects 0.000 claims description 8
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 230000005526 G1 to G0 transition Effects 0.000 claims description 4
- 230000015961 delipidation Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012441 Dermatitis bullous Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 241000101040 Pityriasis Species 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010070834 Sensitisation Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000002052 anaphylactic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 230000013632 homeostatic process Effects 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000008313 sensitization Effects 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 230000037456 inflammatory mechanism Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 description 88
- 210000004027 cell Anatomy 0.000 description 80
- 210000002510 keratinocyte Anatomy 0.000 description 56
- 102100040247 Tumor necrosis factor Human genes 0.000 description 48
- 108090001007 Interleukin-8 Proteins 0.000 description 47
- 102000004890 Interleukin-8 Human genes 0.000 description 47
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 46
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 45
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 43
- 230000000694 effects Effects 0.000 description 42
- 230000003110 anti-inflammatory effect Effects 0.000 description 41
- 239000002609 medium Substances 0.000 description 34
- 231100000673 dose–response relationship Toxicity 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 102100023795 Elafin Human genes 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 28
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 28
- 230000000638 stimulation Effects 0.000 description 28
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000003013 cytotoxicity Effects 0.000 description 26
- 231100000135 cytotoxicity Toxicity 0.000 description 26
- 102000004127 Cytokines Human genes 0.000 description 24
- 108090000695 Cytokines Proteins 0.000 description 24
- 230000003834 intracellular effect Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 230000007423 decrease Effects 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- 230000035899 viability Effects 0.000 description 20
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 19
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 17
- 210000002950 fibroblast Anatomy 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 229930182470 glycoside Natural products 0.000 description 15
- 150000002338 glycosides Chemical class 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 239000012894 fetal calf serum Substances 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 13
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 231100000956 nontoxicity Toxicity 0.000 description 11
- 230000035882 stress Effects 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 9
- 230000020411 cell activation Effects 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000000622 irritating effect Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241000167550 Centella Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 230000000897 modulatory effect Effects 0.000 description 6
- 231100000065 noncytotoxic Toxicity 0.000 description 6
- 230000002020 noncytotoxic effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000021995 interleukin-8 production Effects 0.000 description 5
- 238000002803 maceration Methods 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 229940030999 antipsoriatics Drugs 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- -1 linoleic Chemical compound 0.000 description 2
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 2
- 229940011656 madecassic acid Drugs 0.000 description 2
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- IDQVFXZQPGAVAM-UHFFFAOYSA-N (2alpha,3beta,6beta)-2,3,6,23-Tetrahydroxy-12-oleanen-28-oic acid Natural products C1C(O)C(O)C(C)(CO)C2C(O)CC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C IDQVFXZQPGAVAM-UHFFFAOYSA-N 0.000 description 1
- IDQVFXZQPGAVAM-GGVBUJAJSA-N (4as,6ar,6as,6br,8r,8ar,9r,10r,11r,12ar,14bs)-8,10,11-trihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C IDQVFXZQPGAVAM-GGVBUJAJSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- NKKIKSVUOQQLHL-DMTHEBMLSA-N C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical group C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NKKIKSVUOQQLHL-DMTHEBMLSA-N 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 101710183404 Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 101100350989 Mus musculus Paqr7 gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940084850 beheneth-10 Drugs 0.000 description 1
- 229940106010 beheneth-25 Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000019171 interleukin-1 alpha production Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037204 skin physiology Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215613 | 2002-12-10 | ||
| FR0215613A FR2848117B1 (fr) | 2002-12-10 | 2002-12-10 | Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside |
| PCT/FR2003/003651 WO2004062678A1 (fr) | 2002-12-10 | 2003-12-10 | Procede de preparation d’un extrait de centella asiatica riche en madecassoside et en terminoloside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2509421A1 CA2509421A1 (fr) | 2004-07-29 |
| CA2509421C true CA2509421C (fr) | 2012-02-07 |
Family
ID=32320170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2509421A Expired - Fee Related CA2509421C (fr) | 2002-12-10 | 2003-12-10 | Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7402669B2 (https=) |
| EP (1) | EP1569672B1 (https=) |
| JP (1) | JP4643275B2 (https=) |
| KR (2) | KR20110132629A (https=) |
| CN (1) | CN1774257A (https=) |
| AT (1) | ATE439852T1 (https=) |
| AU (1) | AU2003296799A1 (https=) |
| CA (1) | CA2509421C (https=) |
| DE (1) | DE60328912D1 (https=) |
| ES (1) | ES2329568T3 (https=) |
| FR (1) | FR2848117B1 (https=) |
| WO (1) | WO2004062678A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012015A2 (en) * | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| FR2888114B1 (fr) * | 2005-07-07 | 2009-10-30 | Oreal | Utilisation cosmetique du madecassoside et/ou du terminoloside comme agent empechant ou reduisant l'adhesion des microorganismes sur la surface de la peau et/ou des muqueuses |
| KR20080065641A (ko) * | 2005-11-09 | 2008-07-14 | 바이엘 컨수머 케어 악티엔게젤샤프트 | 센텔라 아시아티카로부터의 화합물의 용도 |
| ATE495749T1 (de) * | 2007-02-12 | 2011-02-15 | Indus Biotech Private Ltd | Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür |
| BRPI0700767B8 (pt) * | 2007-02-15 | 2021-05-25 | Ache Laboratorios Farmaceuticos Sa | composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo |
| FR2914857B1 (fr) * | 2007-04-12 | 2011-01-21 | Dermathologiques D Uriage Lab | Compositions anti-inflammatoires et leur utilisation en cosmetique et/ou en dermatologie |
| WO2008142619A1 (en) * | 2007-05-17 | 2008-11-27 | Izun Pharmaceuticals Corporation | Use of herbal compositions in the protection and enhancement of extracellular matrix components |
| EP2231139B1 (en) * | 2008-01-11 | 2015-02-25 | Shanghai Institute of Pharmaceutical Industry | Therapeutic formulations based on asiatic acid and selected salts thereof |
| FR2929117B1 (fr) | 2008-03-28 | 2010-05-07 | Oreal | Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute |
| FR2929118B1 (fr) | 2008-03-28 | 2010-05-07 | Oreal | Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute |
| US8591961B2 (en) | 2008-09-04 | 2013-11-26 | Allergan, Inc. | Aesthetic treatment of scars and aging skin |
| US8071139B2 (en) * | 2008-09-04 | 2011-12-06 | Alan David Widgerow | Treatment of damaged skin |
| FR2932986B1 (fr) * | 2008-06-26 | 2010-12-10 | Michele Evrard | Composition regeneratrice de la peau |
| CN101323637B (zh) * | 2008-07-29 | 2010-12-22 | 卢照凯 | 一种积雪草甙及其制备方法 |
| CN101407536B (zh) * | 2008-11-27 | 2011-05-18 | 浙江大学 | 一种溶剂结晶法制备高纯度积雪草苷的工艺 |
| FR2943253B1 (fr) | 2009-03-20 | 2011-04-22 | Oreal | Composition contenant l'association de madecassoside, d'une arginine et de polysorbate |
| DE102009026718A1 (de) | 2009-06-04 | 2010-04-15 | Henkel Ag & Co. Kgaa | Hautbehandlung zur Porenverfeinerung II |
| JP2011057634A (ja) * | 2009-09-11 | 2011-03-24 | Rohto Pharmaceutical Co Ltd | 美白用組成物 |
| WO2011043735A1 (en) * | 2009-10-07 | 2011-04-14 | Asian Phytoceuticals Public Company Limited | A composition for modulating immune responses |
| US8685472B2 (en) | 2010-03-01 | 2014-04-01 | Access Business Group International Llc | Skin whitening composition containing chia seed extract |
| CA2802154C (en) * | 2010-06-10 | 2017-02-28 | Indus Biotech Private Limited | A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof |
| FR2964570A1 (fr) | 2010-09-09 | 2012-03-16 | Burgundy | Procede de preparation d'un extrait de centella asiatica |
| WO2012050763A2 (en) | 2010-09-29 | 2012-04-19 | Access Business Group International Llc | Chia seed extract and related method of manufacture |
| CN102603854A (zh) * | 2011-01-25 | 2012-07-25 | 苏州宝泽堂医药科技有限公司 | 一种从积雪草中提取积雪草皂苷的方法 |
| KR101245563B1 (ko) * | 2011-03-16 | 2013-03-21 | 바이오스펙트럼 주식회사 | 마데카소사이드를 함유하는 피부 미백제 |
| JP5926506B2 (ja) * | 2011-06-23 | 2016-05-25 | バイオランド・リミテッド | コラーゲン産生促進剤の製造方法、ｍｍｐ−１阻害剤の製造方法及び皮膚外用組成物の製造方法 |
| DE102011083293A1 (de) | 2011-09-23 | 2013-03-28 | Henkel Ag & Co. Kgaa | Wasserfreie Formulierungen mit kühlender Wirkung |
| CN102367263B (zh) * | 2011-11-11 | 2013-05-29 | 上海师范大学 | 一种分离纯化积雪草三萜酸单葡萄糖苷的方法 |
| WO2014003224A1 (en) * | 2012-06-29 | 2014-01-03 | Bio Spectrum, Inc. | Compositions for whitening skin comprising madecassoside |
| US12440530B2 (en) | 2013-03-01 | 2025-10-14 | Envy Medical, Inc. | Skin solution with solubilized bakuchiol |
| FR3005575B1 (fr) * | 2013-05-20 | 2016-01-01 | Oreal | Composition cosmetique comprenant un agent antipelliculaire, un bisabolol et un compose de type madecassoside, et procede de traitement cosmetique |
| CN105168051A (zh) * | 2015-09-16 | 2015-12-23 | 任海锋 | 肤色遮盖液 |
| CN105267056A (zh) * | 2015-12-01 | 2016-01-27 | 江苏隆力奇生物科技股份有限公司 | 一种具有抗皱祛皱功能的护肤化妆品组合物及其应用 |
| CN107412235A (zh) * | 2017-06-28 | 2017-12-01 | 上海交通大学 | 一种积雪草中促进pc12细胞分化的单体组合及其应用 |
| CN107903296B (zh) * | 2017-11-29 | 2021-01-26 | 桂林融通科技有限公司 | 羟基积雪草苷的提取方法 |
| WO2020112590A1 (en) | 2018-11-27 | 2020-06-04 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Solubilised centella asiatica extract |
| CN112773806B (zh) * | 2019-11-06 | 2024-03-19 | 鲁南制药集团股份有限公司 | 包含淫羊藿苷元和羟基积雪草酸的药物组合物的医药用途 |
| CN111285916B (zh) * | 2020-02-14 | 2021-07-02 | 浏阳朗林生物科技有限公司 | 一种积雪草总苷含量高的积雪草提取物的制备方法 |
| FR3117834B1 (fr) * | 2020-12-17 | 2023-11-10 | Oreal | Composition cosmétique biphase comprenant un acide aminé et deux acides spécifiques |
| CN112957379B (zh) * | 2021-02-20 | 2022-04-08 | 上海珈凯生物科技有限公司 | 一种积雪草提取物的提取方法 |
| WO2023036404A1 (en) | 2021-09-07 | 2023-03-16 | Symrise Ag | Taste balancing botanical compounds |
| KR102725267B1 (ko) * | 2021-10-19 | 2024-11-01 | 동국제약 주식회사 | 병풀 정량 추출물 및 마데카소사이드를 유효성분으로 함유하는 화장료 조성물 |
| WO2023123046A1 (en) * | 2021-12-29 | 2023-07-06 | L'oreal | Composition for caring for the skin |
| CN115228432B (zh) * | 2022-05-31 | 2023-04-25 | 西南科技大学 | 用于放射性核素富集的生物质衍生碳包裹纳米零价铁材料的制备及应用 |
| CN114989239B (zh) * | 2022-07-05 | 2023-04-18 | 广西昌洲天然药业有限公司 | 一种从积雪草中分离羟基积雪草苷方法及计算机存储介质 |
| KR102786604B1 (ko) * | 2022-12-12 | 2025-03-26 | 주식회사 코스모바이오 | 병풀로부터 아시아티코사이드 및 마데카소사이드의 분리 정제 방법 |
| KR20240129658A (ko) | 2023-02-20 | 2024-08-28 | 국립한국교통대학교산학협력단 | 병풀 착즙물을 포함하는 항염증 조성물 |
| CN116407478A (zh) * | 2023-05-11 | 2023-07-11 | 杭州以息互联网科技有限公司 | 一种温和的祛痘组合物及其应用 |
| KR102883448B1 (ko) * | 2023-05-16 | 2025-11-06 | 대봉엘에스 주식회사 | 병풀 추출물을 포함하는 화장료 조성물 |
| CN117530893A (zh) * | 2023-12-23 | 2024-02-09 | 上海琦成化妆品有限公司 | 一种抗炎修复组合物及其应用 |
| CN117898962A (zh) * | 2024-01-23 | 2024-04-19 | 江南大学 | 一种具有皮肤修复功效的羟基积雪草苷组合物及其应用 |
| KR20250117531A (ko) | 2024-01-26 | 2025-08-05 | 국립한국교통대학교산학협력단 | 병풀 유래의 항염증 조성물 |
| FR3162624A1 (fr) | 2024-05-31 | 2025-12-05 | L'oreal | Composition comprenant au moins un actif antipelliculaire, au moins un agent antioxydant et au moins 35% en poids d’un monoalcool en C1 à C6 |
| CN121489992A (zh) * | 2026-01-12 | 2026-02-10 | 上海华之沃生物医药科技有限公司 | 积雪草提取物的制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5975M (https=) * | 1966-08-08 | 1968-04-22 | ||
| KR910002518B1 (ko) * | 1989-03-09 | 1991-04-23 | 동국제약 주식회사 | 적설초에서 게닌성분 및 아시아티코사이드의 분리방법 |
| KR100357848B1 (ko) | 1996-04-23 | 2002-12-18 | 더 프록터 앤드 갬블 캄파니 | 비타민비3화합물을포함하는피부외관을조절하기위한국소용조성물 |
| KR100228873B1 (ko) * | 1997-03-24 | 1999-11-01 | 강재헌 | 센텔라아시아티카에서 분리한 아시아티코사이드와 마테카소 사이드의 수용성 추출물을 함유한 간세포 및 항간섬유화 치료제 |
| FR2768927B1 (fr) * | 1997-10-01 | 2000-01-21 | Lvmh Rech | Utilisation de l'acide ellagique, de ses sels, de ses complexes metalliques, de ses derives mono- ou poly-ethers, mono- ou poly-acyles dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie |
| WO2001019365A1 (en) * | 1999-09-15 | 2001-03-22 | Roche Consumer Health Ag | Pharmaceutical and/or cosmetical compositions |
| US6416769B1 (en) * | 2000-03-03 | 2002-07-09 | Australian Importers, Ltd. | Cosmetic compositions comprising exfoliating enzymes and uses thereof |
-
2002
- 2002-12-10 FR FR0215613A patent/FR2848117B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-10 DE DE60328912T patent/DE60328912D1/de not_active Expired - Lifetime
- 2003-12-10 AU AU2003296799A patent/AU2003296799A1/en not_active Abandoned
- 2003-12-10 WO PCT/FR2003/003651 patent/WO2004062678A1/fr not_active Ceased
- 2003-12-10 AT AT03815106T patent/ATE439852T1/de not_active IP Right Cessation
- 2003-12-10 EP EP03815106A patent/EP1569672B1/fr not_active Expired - Lifetime
- 2003-12-10 CA CA2509421A patent/CA2509421C/fr not_active Expired - Fee Related
- 2003-12-10 ES ES03815106T patent/ES2329568T3/es not_active Expired - Lifetime
- 2003-12-10 KR KR1020117026265A patent/KR20110132629A/ko not_active Ceased
- 2003-12-10 US US10/537,936 patent/US7402669B2/en not_active Expired - Lifetime
- 2003-12-10 JP JP2004566117A patent/JP4643275B2/ja not_active Expired - Lifetime
- 2003-12-10 KR KR1020057010638A patent/KR101122786B1/ko not_active Expired - Fee Related
- 2003-12-10 CN CNA2003801095973A patent/CN1774257A/zh active Pending
-
2008
- 2008-01-22 US US12/009,696 patent/US8163706B2/en not_active Expired - Fee Related
-
2012
- 2012-03-21 US US13/425,641 patent/US8486900B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60328912D1 (de) | 2009-10-01 |
| AU2003296799A1 (en) | 2004-08-10 |
| JP4643275B2 (ja) | 2011-03-02 |
| US20080118581A1 (en) | 2008-05-22 |
| KR101122786B1 (ko) | 2012-04-12 |
| FR2848117B1 (fr) | 2006-08-04 |
| EP1569672A1 (fr) | 2005-09-07 |
| JP2006516962A (ja) | 2006-07-13 |
| CN1774257A (zh) | 2006-05-17 |
| US8486900B2 (en) | 2013-07-16 |
| EP1569672B1 (fr) | 2009-08-19 |
| US20120178706A1 (en) | 2012-07-12 |
| KR20110132629A (ko) | 2011-12-08 |
| ATE439852T1 (de) | 2009-09-15 |
| CA2509421A1 (fr) | 2004-07-29 |
| WO2004062678A1 (fr) | 2004-07-29 |
| US8163706B2 (en) | 2012-04-24 |
| KR20060069349A (ko) | 2006-06-21 |
| US20060106206A1 (en) | 2006-05-18 |
| ES2329568T3 (es) | 2009-11-27 |
| US7402669B2 (en) | 2008-07-22 |
| FR2848117A1 (fr) | 2004-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2509421C (fr) | Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside | |
| JP5361820B2 (ja) | グルタチオン増強用組成物 | |
| EP2654766A1 (fr) | Extrait de pulpe et/ou de peau d'avocat riche en polyphenols et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant | |
| FR2938439A1 (fr) | Extrait de parties aeriennes d'avoine recoltees avant epiaison | |
| EP3119382A2 (fr) | Applications cosmétiques et pharmaceutiques de l'acide gallique et de dérivés de l'acide gallique | |
| KR102403354B1 (ko) | 피부장벽강화 및 피부보습용 조성물 | |
| JP2011088845A (ja) | インボルクリン発現抑制剤 | |
| US8455023B2 (en) | Composition for inhibiting melanogenesis and use thereof | |
| WO2012081370A1 (ja) | エンドセリン作用抑制剤及び美白剤 | |
| EP0809484A2 (fr) | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de bertholletia | |
| EP4099976A1 (fr) | Extrait de murraya koenigii et son utilisation en cosmetique | |
| JP4197194B2 (ja) | 細胞間接着抑制用経口投与剤 | |
| EP1743628A1 (fr) | Composition cosmétique comprenant un extrait d'algue rouge comprenant une association de floridoside et d'acide iséthionique. | |
| JP2019147824A (ja) | 黒生姜含有組成物 | |
| KR101695372B1 (ko) | 까치밥나무 추출물을 함유하는 피부 주름 개선 및 예방용 조성물 | |
| KR102272637B1 (ko) | 올벚나무를 포함하는 항염증용 조성물 | |
| FR3138029A1 (fr) | Extrait anhydre de feuilles sans tige d’hippophae rhamnoides ou composition comprenant ledit extrait pour utilisation pour maintenir et/ou ameliorer la microcirculation cutanee et composition comprenant ledit extrait | |
| JP7217550B2 (ja) | 黒生姜含有組成物 | |
| JP7828636B2 (ja) | 糖尿病改善剤 | |
| JP2012140405A (ja) | ベオミセス酸高含有ムシゴケ抽出物の製造方法 | |
| WO2021140131A1 (fr) | Utilisation de la taxodione comme agent anti-glycation | |
| JP2026057176A (ja) | Ｎｅｔｒｉｎ－１産生促進剤 | |
| BE1027772A1 (fr) | Composition de ginseng pour ameliorer l'etat de la peau et son utilisation pour le traitement d'une maladie dermatologique | |
| JP2007084460A (ja) | 美肌用組成物 | |
| FR2903305A1 (fr) | Utilisation d'extraits vegetaux en tant que principes actifs amincissants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191210 |